
- 1 day ago
Marianne De Backer talks about joining Vir Biotechnology and shares her vision for the future

- 2 days ago
Alto Neuroscience's CEO on why MDD data at #ACNP2023 may validate its precision medicine approach

- Nov 21
BridgeBio's Neil Kumar reviews #AHA23 data and the company's pipeline and finances

- Nov 20
Checking in with Cytokinetics ahead of the SEQUOIA-HCM P3 study result due in December

- Nov 3
Carisma's CEO discusses their Moderna-partnered CAR-M preclinical late breaker at #SITC23

- Nov 2
Ambrx's CEO & CSO discuss the ADC space and recent #ESMO23 data

- Nov 2
Kura Oncology's CEO gives an update on Q3 earnings day

- Oct 25
The Co-CEO of Renibus Therapeutics shares a company's perspective of the N. Texas biotech ecosystem

- Oct 20
A deep dive into the oncology target PRMT5 with the CEO of Tango Therapeutics

- Oct 19
Brushing up on the science of obesity with Rhythm Pharmaceuticals’ CEO

- Oct 18
Monte Rosa's CEO discusses yesterday's data for MRT-2359 in MYC-driven solid tumors

- Oct 16
Amylyx's Co-CEOs comment on Friday's European CHMP decision on their ALS therapy

- Oct 11
The CEO of eGenesis elaborates on today's Nature paper using pig kidneys for transplantation in NHPs

- Oct 11
The Head of Bayer in the US on pharma and a new $250M cell Tx facility in Berkeley, CA. #HLTH2023

- Oct 10
Analyzing Nanobiotix's P1 Head & Neck data for the radioenhancer NBTXR3 from #ASTRO2023

- Oct 9
Delfi Diagnostics' team on launching the FirstLook Lung cancer blood screening test at #HLTH2023

- Sep 28
Harbinger Health’s Steve Hahn on the science of early cancer Dx after raising a $140M Series B

- Sep 25
Learning about molecular glues from the CEO of Orionis Biosciences following a recent Genentech deal

- Sep 18
Rome Therapeutics’ CEO on the science of the 'Dark Genome' and last week’s $72M Series B extension

- Sep 18
Generate Biomedicines' Mike Nally on Thursday's $273M Series C and computational drug development